新股首日 | 麦科医药-B(02335)首挂上市早盘高开86.92% 核心产品MT1013正处于III期临床阶段

智通财经06-24

智通财经APP获悉，麦科医药-B(02335)首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。公司的核心产品MT1013为一款自主研发、处于III期阶段的双靶点受体激动剂多肽，可同时...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2645697863?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-24 09:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645697863","market":"us","top_or_hot":-1,"title":"新股首日 | 麦科医药-B(02335)首挂上市 早盘高开86.92% 核心产品MT1013正处于III期临床阶段","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，麦科医药-B(02335)首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。公司的核心产品MT1013为一款自主研发、处于III期阶段的双靶点受体激动剂多肽，可同时...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457891.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股首日 | 麦科医药-B(02335)首挂上市 早盘高开86.92% 核心产品MT1013正处于III期临床阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股首日 | 麦科医药-B(02335)首挂上市 早盘高开86.92% 核心产品MT1013正处于III期临床阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-24 09:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1457891.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，麦科医药-B(02335)首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。公司的核心产品MT1013为一款自主研发、处于III期阶段的双靶点受体激动剂多肽，可同时...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457891.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1457891.html","article_id":"2645697863","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645697863","pubTimestamp":1782264328,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，麦科医药-B首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。预计公司的MT1013将于2028年初商业化，公司将实行双轨商业化策略：在国内透过与第三方合约销售组织合作，在国际上则透过授权合作伙伴关系。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"III":"信息服务","IPOS":"Renaissance International IPO ETF","02335":"麦科医药-B","BK4134":"信息科技咨询与其它服务"},"translate_title":"The first day of new shares | Maike Pharmaceutical-B (02335) first listed and opened 86.92% higher in early trading. The core product MT1013 is in the phase III clinical stage","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02335":1.5,"III":1.5,"IPOS":1.5},"content_text":"智通财经APP获悉，麦科医药-B(02335)首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。公司的核心产品MT1013为一款自主研发、处于III期阶段的双靶点受体激动剂多肽，可同时靶向CaSR及OGP受体，主要为治疗慢性肾病继发性甲状旁腺功能亢进症(CKD-SHPT)而设计，并具有扩展至其他适应症(如伴有骨质疏松的慢性肾脏病的矿物质和骨代谢异常(CKD-MBD)及非透析CKD-SHPT)的潜力截至最后实际可行日期，公司尚未就任何候选药物取得上市批准，亦未从产品销售中产生任何收益。预计公司的MT1013将于2028年初商业化，公司将实行双轨商业化策略：在国内透过与第三方合约销售组织(CSO)合作，在国际上则透过授权合作伙伴关系。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645697863","isCrawlerRequest":true}

新股首日 | 麦科医药-B(02335)首挂上市 早盘高开86.92% 核心产品MT1013正处于III期临床阶段

精彩评论

新股首日 | 麦科医药-B(02335)首挂上市早盘高开86.92% 核心产品MT1013正处于III期临床阶段